knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 00:08:55 - browse：58485

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Impact of Dobbs ruling felt at reproductive medicine meeting

hotspot

WSS

2023 STAT Wunderkinds: get to know the winners

CDC marks new Covid

With psoriasis trial ahead, Alumis raises $259 million

Medicare reduced heart disease by changing how it pays doctors

UnitedHealth quietly bought dozens of outpatient centers

Pharmacists can make shortage drugs, but at what cost?

hotspot

knowledge

entertainment

Drug repurposing or repositioning? The language matters

Senate committee scrutinizes Medicare Advantage brokers

How one medical school became remarkably diverse

Medicare reduced heart disease by changing how it pays doctors

Medicare details structure of new drug price negotiation program

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

After affirmative action ruling, medical educators look to 'holistic review'

Beam Therapeutics to lay off 20% of its staff, re

New air purifier tech could be key to improving indoor air quality

UnitedHealth quietly bought dozens of outpatient centers

leisure time

Will Ozempic

With psoriasis trial ahead, Alumis raises $259 million

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The drug industry has found itself all alone in Washington

FDA gives detailed accounting of AI

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

hotspot

hotspot

focus